Related Articles
Aspirin Use Among Breast Cancer Survivors: Navigating Negative Results, Age, and Health Equity
Investigators uncovered critical issues related to health equity and aging that may have broad implications for cancer trials among breast cancer survivors receiving aspirin, according…
Pasi A. Jänne, MD, PhD, on NSCLC, Osimertinib, Chemotherapy: Update From FLAURA2
Pasi A. Jänne, MD, PhD, of Dana-Farber Cancer Institute, discusses an exploratory analysis from the FLAURA2 study, which indicates that baseline levels of plasma EGFR…
Immunotherapy Plus FOLFIRI for Advanced Gastric/Gastroesophageal Junction Adenocarcinoma
In a French noncomparative phase II trial, investigators established limited activity of FOLFIRI (leucovorin, fluorouracil, and irinotecan) plus durvalumab or durvalumab/tremelimumab in the second-lin…
Kelly K. Hunt, MD, on Breast Cancer and Neoadjuvant Therapy: Expert Commentary
Kelly K. Hunt, MD, of The University of Texas MD Anderson Cancer Center, discusses the benefits to patients with neoadjuvant therapy in advanced, inoperable breast…
Impact of Propofol Exposure on Neurocognitive Outcomes in Children With High-Risk ALL
Exposure to propofol was associated with an increased risk of impairment in reaction time/processing speed at 1 year after treatment in children with high-risk B-cell…
Combination of Preketone Supplements and Immunotherapy May Be Effective in Patients With Prostate Cancer
A preclinical study suggests that the addition of a component of the ketogenic diet—a preketone dietary supplement—to immunotherapy may potentially be effective in treating prostate…
Kelly K. Hunt, MD, on Breast Cancer and Neoadjuvant Therapy: Expert Commentary
Kelly K. Hunt, MD, of The University of Texas MD Anderson Cancer Center, discusses the benefits to patients with neoadjuvant therapy in advanced, inoperable breast…
Neoadjuvant Chemoimmunotherapy in Patients With Early-Stage NSCLC
A systematic review and meta-analysis found that neoadjuvant chemoimmunotherapy was associated with improved event-free survival and pathologic complete response compared with neoadjuvant chemotherapy…
Barriers to Autologous Hematopoietic Cell Transplantation in Multiple Myeloma
Investigators have uncovered persistent racial and social disparities that may impede access to autologous hematopoietic cell transplantation for some patients with multiple myeloma.
FDA Approves Trastuzumab Biosimilar Trastuzumab-strf
The FDA has approved trastuzumab-strf (Hercessi), a biosimilar to trastuzumab (Herceptin), for the treatment of HER2-overexpressing breast cancer and gastric or gastroesophageal junction adenocarcinom…